Kin Seng Liem

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Topics

Randomized Controlled Trial

Mesenchymal Stem Cells

Hepatitis B Virus

Ejection Fraction

Top Venues

Journal of viral hepatitis

Alimentary pharmacology & therapeutics

Liver international : official journal of the International Association for the Study of the Liver

This page only lists publications with an associated author ORCID identifier.

Publications

Mina S Farag, Margo J H van Campenhout, Milan J Sonneveld, Scott Fung, Karel J van Erpecum, David K Wong, Elke Verhey, Robert de Man, Robert J De Knegt, Johannes T Brouwer, Hubertus C Baak, Jordan J Feld, Kin Seng Liem, André Boonstra, Bettina E Hansen, Harry L A Janssen
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study). Journal of viral hepatitis 31 (4) (2024)
Mina S Farag, Margo J H van Campenhout, Milan J Sonneveld, Scott Fung, Karel J van Erpecum, David K Wong, Elke Verhey, Robert de Man, Robert J De Knegt, Johannes T Brouwer, Hubertus C Baak, Jordan J Feld, Kin Seng Liem, André Boonstra, Bettina E Hansen, Harry L A Janssen
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study). Journal of viral hepatitis 31 (4) (2024)
Mina S Farag, Margo J H van Campenhout, Milan J Sonneveld, Scott Fung, Karel J van Erpecum, David K Wong, Elke Verhey, Robert de Man, Robert J De Knegt, Johannes T Brouwer, Hubertus C Baak, Jordan J Feld, Kin Seng Liem, André Boonstra, Bettina E Hansen, Harry L A Janssen
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study). Journal of viral hepatitis (2024)
Mina S Farag, Margo J H van Campenhout, Milan J Sonneveld, Scott Fung, Karel J van Erpecum, David K Wong, Elke Verhey, Robert de Man, Robert J De Knegt, Johannes T Brouwer, Hubertus C Baak, Jordan J Feld, Kin Seng Liem, André Boonstra, Bettina E Hansen, Harry L A Janssen
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study). Journal of viral hepatitis 31 (4) (2024)
Kin Seng Liem, Heng Chi, Scott Fung, David K Wong, Colina Yim, Seham Noureldin, Jiayun Chen, Robert A de Man, Arif Sarowar, Jordan J Feld, Bettina E Hansen, Jin-Lin Hou, Jie Peng, Harry L A Janssen
Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B. Journal of viral hepatitis 29 (11) (2022)
Kin Seng Liem, David K Wong, Scott Fung, Alireza Zahirieh, Colina Yim, Wayel R Zanjir, Jordan J Feld, Bettina E Hansen, Harry L A Janssen
Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients. Journal of viral hepatitis 28 (1) (2020)
Kin Seng Liem, Margo J H van Campenhout, Qing Xie, Willem Pieter Brouwer, Heng Chi, Xun Qi, Liang Chen, Fehmi Tabak, Bettina E Hansen, Harry L A Janssen
Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. Alimentary pharmacology & therapeutics 49 (4) (2020)
Kin Seng Liem, Colina Yim, Thomas D Ying, Wayel R Zanjir, Scott Fung, David K Wong, Hemant Shah, Jordan J Feld, Bettina E Hansen, Harry L A Janssen
Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B. Liver international : official journal of the International Association for the Study of the Liver 39 (8) (2019)
Kin Seng Liem, Harry L A Janssen
Editorial: identifying candidates for pegylated interferon add-on to entecavir therapy in patients with HBeAg-positive chronic hepatitis B - authors' reply. Alimentary pharmacology & therapeutics 49 (5) (2019)
Kin Seng Liem, Scott Fung, David K Wong, Colina Yim, Seham Noureldin, Jiayun Chen, Jordan J Feld, Bettina E Hansen, Harry L A Janssen
Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut 68 (12) (2019)